# Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

> **NCT07156019** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 32 (estimated)

## Conditions studied

- Neuroendocrine Carcinomas (NEC)

## Interventions

- **DRUG:** Sintilimab+Temozolomide+Surufatinib

## Key facts

- **NCT ID:** NCT07156019
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07156019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07156019, "Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07156019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*